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Prostate cancer patients managed with androgen-deprivation therapy usually recur after a few
years and the disease gradually becomes castration-resistant prostate cancer (CRPC). The role of
tumor cell plasticity, including processes such as transdifferentiation and epithelial-mesenchymal
transition, is pivotal in the development of androgen receptor (AR)-indifferent tumor variants (1).
Cell plasticity may allow CRPC progression and metastasis by favoring reactivation of AR signaling
as a result of different mechanisms of transcriptome reprogramming. Interestingly, dissection of
such mechanisms can lead to the identification of novel vulnerabilities of aggressive tumor cells
that can be targeted therapeutically. The recent work by Zhao et al. (2) identified the vasopressin
receptor 1a (AVPR1a) as a critical effector in CRPC expressing the AR coactivator VAV3 and the
constitutively active AR variant AR-V7. They demonstrated that ectopic expression of AVPR1a
is capable of conferring castration resistance and agonist treatment with the receptor ligand, the
natural hormone arginine vasopressin, activates ERK and CREB, signaling molecules known to
promote prostate cancer progression. Interestingly, depletion of AVPR1a or inhibition by the
selective AVPR1a antagonist relcovaptan resulted in decreased CRPC cell proliferation and reduced
bone metastatic growth in vivo.
We completely agree with the authors in the sense that AVPR1a can be a potential target
for CRPC therapy. We believe that clinical trials with relcovaptan are warranted, particularly
in patients with bone-metastatic disease for which therapeutic options are limited. However, we
want to point out that these results could be revealing other untapped antitumor properties of
the vasopressin system-related drugs against prostate cancer cells. Our team has reported that
the vasopressin analog desmopressin, a selective agonist for the vasopressin receptor 2 (AVPR2),
significantly reduced tumor cell growth and migration in AR-negative CRPC (3). In vitro exposure
to desmopressin also induced a dramatic decrease of the neuroendocrine markers chromogranin
and neuron-specific enolase in aggressive CRPC cells (3). In prostate cancer, neuroendocrine
transdifferentiation is known to be related with transition toward AR-indifference and metastatic
phenotype. Besides, recent studies in orthotopic and heterotopic models of CRPC in athymic nude
mice demonstrated an enhanced efficacy of docetaxel in combination with desmopressin (4, 5).
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Agonist activation of AVPR2 present in various human
cancer cell lines has been associated with triggering of
antiproliferative signaling pathways involving canonical
adenylate cyclase/cAMP/PKA axis activation. cAMP blocks the
proliferation of many cell types, both normal and transformed,
through multiple downstream effectors. It is known that
increased cAMP levels inhibit the Raf/MAPK/ERK signaling
pathway in a PKA-dependent manner, but this is not the only
mitogenic pathway impaired by cAMP (6). Although cytostatic
effect after AVPR2 stimulation is robust, the underlying
mechanism is intriguing since AVPR2-mediated cell signaling
may eventually lead to phosphorylation of hundreds of PKA
substrates granting a complex and seemingly contradictory
framework of signaling pathways as evidenced in immortalized
epithelial cells after stimulation with desmopressin (7). In this
sense, high cAMP levels and PKA activation may eventually
lead to phosphorylation and activation of CREB. However,
many factors contribute to final cell response. It is known that
cAMP can either stimulate or inhibit tumor cell apoptosis,
and PKA is able to mediate cAMP-promoted proapoptotic
responses depending on the cell type and the cell context (8). In
FIGURE 1 | Mechanisms of action of the vasopressin system-related drugs in hormone-resistant cancer. (A) Selective AVPR1a-antagonist relcovaptan blocks
mitogenic signals triggered by natural ligand vasopressin. (B) Activation of AVPR2 by selective agonist desmopressin inhibits cancer cell growth by activating
antiproliferative signaling pathways. AC, adenylyl cyclase; ATP, adenosine triphosphate; AVPR1a, arginine vasopressin receptor type 1A; AVPR2, arginine vasopressin
receptor type 2; cAMP, cyclic adenosine monophosphate; CREB, cAMP-response-element-binding protein; DAG, diacylglycerol; ER, endoplasmic reticulum; ERK1/2,
extracellular signal–regulated kinases; Gq/11, Gq protein alpha subunit; Gs, Gs protein alpha subunit; IP3, inositol-1,4,5-trisphosphate; PIP2, phosphatidyl
inositol-bisphosphate; PKA, cAMP-dependent protein kinase; PLC, phospholipase C.
addition, it has been reported a crosstalk of cAMP/PKA that can
inhibit RhoA-mediated signaling, thus affecting the aggressive
behavior of CRPC cells (9). Taken together, it seems that CREB
activation is not prominent after AVPR2 selective agonist
action on cancer cells, being favored certain antiproliferative
signals. In breast cancer cells expressing AVPR1a and AVPR2,
natural vasopressin can activate both receptors but its affinity
is higher for AVPR1a and the number of functional AVPR2
tends to be relatively low. Thus, vasopressin elicits AVPR1a-
dependent proliferative signals mediated by ERK activation that
clearly predominate over AVPR2-dependent antiproliferative
signals (10). On the contrary, when AVPR1a is blocked by
selective antagonists such as relcovaptan or tumor cells are
exposed to specific AVPR2 agonists such as desmopressin,
significant antiproliferative effects are achievable in hormone-
resistant breast cancer cell lines (10, 11). Desmopressin also
contributed to reduce aggressiveness of mammary tumors
during chemotherapy in an immunocompetent mouse model
(12). We have conducted a Phase 2 dose-escalation clinical
trial of desmopressin as a perioperative adjuvant in patients
with breast cancer (NCT01606072). Desmopressin appeared
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safe when administered in two slow infusions before and after
surgery, and a rapid postoperative drop in circulating tumor cells
was detected after treatment (13). In addition, we documented
a reduced intraoperative bleeding associated to the well-known
hemostatic effects of the compound (13).
From a wider perspective, the stimulating article by Zhao et al.
(2) ratifies the relevance of the vasopressin system for searching
novel therapeutic targets in hormone-resistant cancer and
particularly in CRPC (Figure 1; see also Supplementary Table 1
for preclinical data summary). In this context, repurposing
of already-used drugs with a non-oncology primary purpose
stands as an interesting strategy to offer effective therapeutic
options to cancer patients, allowing faster development and
reducing safety concerns (14). The selective AVPR1a antagonist
relcovaptan is a small-molecule inhibitor that has been
safely and effectively used in clinical trials for Raynaud
syndrome, dysmenorrhea and preterm labor. The specific
AVPR2 agonist desmopressin is a synthetic peptide compound
that has been employed for decades as an antidiuretic
in the treatment of diabetic insipidus and enuresis, and
as a hemostatic agent for the management of bleeding
disorders, with a history of good tolerability and clinical
effectiveness. Both compounds constitute promising therapeutic
approaches for CRPC that deserve clinical testing either alone
or in combination, as well as concurrently with standard
chemotherapy regimens.
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